Philip Morris International (NYSE:PM) is urging the U.S. Food and Drug Administration to allow the company to continue marketing its heated tobacco products in the U.S. as a “modified risk tobacco ...

Recent Share Performance and Business Snapshot Philip Morris International (PM) has drawn investor attention after a period ...

Philip Morris International Inc. PM is accelerating its shift from traditional tobacco to reduced-risk products, with strong momentum in its flagship offerings — IQOS and ZYN. In the first quarter of ...

Philip Morris International operated outside the U.S. for years, but has entered the market with smoke-free products. Sales of Iqos Iluma in the United States could be a game changer once approved.

Philip Morris International’s PM smoke-free business is gaining scale, and the performance of its flagship products, IQOS and ZYN, is central to this trajectory. In the second quarter of 2025, the ...

Are you considering investing in Philip Morris International (NYSE: PM)? As one of the leading companies in the tobacco industry, Philip Morris has drawn attention from both seasoned investors and ...

A pioneer in modified risk tobacco products, Philip Morris International is the only company to have received a modified risk marketing claim for an electronic nicotine device. FDA concludes “Evidence ...

Altria Group, Inc. (MO) and Philip Morris International Inc. (PM) rank among the most influential players in the global tobacco industry, each operating with distinct geographic exposure and strategic ...

Philip Morris International Inc.’s PM second-quarter 2025 results spotlight the central question for its long-term transformation: Can smoke-free momentum truly outweigh persistent declines in ...